Neoplasia/BPH

	Efficacy and safety of Î±1-adrenergic receptor antagonists in managing acute urinary retention secondary to benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials. Arch Ital Urol Androl Althunayan GS, Almuossa BM, Almulla MA, Alshazly H, Al-Hayani AM, Hetou K. PMID: 42803674 [PubMed - indexed for MEDLINE]
	Real-world outcomes of transurethral resection of the prostate: a Portuguese cohort. Arch Ital Urol Androl Pedrosa R, Paço P, Sousa T, Rêgo A, Tavares Silva E, Temido P, Figueiredo A. PMID: 42803669 [PubMed - indexed for MEDLINE]
	Postoperative administration of a combination of Phycocyanin, PEA and Selenium following prostatic deobstructive surgery: a preliminary clinical study. Arch Ital Urol Androl Saitta G, Striano V, Di Salvatore S, Fontana G, Di Paola G, Ceresoli AS, Mantovani FA, Meazza AL, Seveso M. PMID: 42803668 [PubMed - indexed for MEDLINE]
	Early functional and oncological outcomes after robot-assisted radical prostatectomy in D'Amico high-risk prostate cancer: a prospective cohort study. Arch Ital Urol Androl Keller JM, Stankovic M, Wieder T, Wolff L, Mendes J. PMID: 42803667 [PubMed - indexed for MEDLINE]
	Let us trace our path from glass slide to virtual slide and artificial intelligence. Arch Ital Urol Androl Montironi R, Cimadamore A, Trinchieri A. PMID: 42803663 [PubMed - indexed for MEDLINE]
	Global trends and hotspots in bladder cancer: A bibliometric analysis (2016-2025). Urologia Heer R, Farrokhi M. PMID: 42803329 [PubMed - as supplied by publisher]
	Kidney impairment post 177Lu-PSMA radioligand therapy in metastatic prostate cancer. Nucl Med Commun Osbourne J, Hofman MS, Ruderman I. PMID: 42802891 [PubMed - as supplied by publisher]
	Stage migration in prostate cancer: the role of PSMA-PET in identifying oligometastatic disease. Eur J Nucl Med Mol Imaging Mattana F, Luzzago S, Dragonetti V, Kasivisvanathan V, Conlon S, Castellucci P, Farolfi A, Miszczyk M, Techma, Rajwa P, Shariat SF, Zattoni F, Reitano G, Briganti A, Montorsi F, Frassoni S, Bagnardi V, Gandaglia G, Ceci F. PMID: 42802268 [PubMed - as supplied by publisher]
	Androgen Receptor-Immune Crosstalk in Metastatic Castration-Resistant Prostate Cancer: From Context-Dependent Remodeling to Biomarker-Guided Translation. Prostate Li L, Feng R, Zha B, Yang S, Wang G, Jiang Z, Mou J, Gao F. PMID: 42801730 [PubMed - as supplied by publisher]
	Insulin-Like Growth Factor Axis and Survival in Metastatic Hormone-Sensitive Prostate Cancer: Post-Hoc Analysis From the ENZAMET Phase 3 Trial. Prostate Cilento MA, Lin HM, Yeung N, Kim RMN, Portman N, Stockler MR, Martin AJ, Subhash V, Yip S, Butler LM, Marschner IC, Meikle PJ, Azad AA, Davis ID, Horvath LG, Sweeney CJ. PMID: 42801727 [PubMed - as supplied by publisher]
	A Phase II Trial Using Grape Seed Extract for Prostate Cancer Patients With Nonmetastatic Prostate-Specific Antigen Progression After Local Therapy. Mol Carcinog Maroni P, Manalo TA, Baker H, Kessler ER, Nicklawsky A, Trevisanut V, Flaig TW, Lam ET, Moore JC, Gao D, Raina K, Agarwal R. PMID: 42801665 [PubMed - as supplied by publisher]
	Analysis of NAT2 coding variants, combined genotypes, and haplotypes in prostate cancer susceptibility: a case-control study in an Iraqi Arab population. Mol Biol Rep Tarish MA, Kudhair BK. PMID: 42801388 [PubMed - indexed for MEDLINE]
	Plasma circulating tumor deoxyribonucleic acid methylation enables noninvasive disease stratification beyond prostate-specific antigen in prostate cancer. Prostate Int Kim DW, Jung MH, Cho H, Cha J, Han KH, Choi JH, Park M, Park SH, Oh CK, Lee ST, Kim YJ, Chung JS. PMID: 42801146 [PubMed]
	Patients with high-risk features on active surveillance for prostate cancer. Prostate Int Goodman S, Dua Y, Pan HYC, Perera S, Sathianathen N, Perera M, Murphy D, Lawrentschuk N. PMID: 42801144 [PubMed]
	A cfDNA-based DNA methylation classifier for distinguishing prostate cancer from benign prostatic hyperplasia. Prostate Int Lee JH, Oh HJ, Koo HJ, Kim MY, Kim CS, Lim B, Lee JY, Park WY. PMID: 42801083 [PubMed]
	Multicentre evaluation of artificial intelligence risk classification for detection of clinically significant prostate cancer on biparametric MRI. Eur Radiol Guenzel K, Poirot MG, van Loon A, Messina E, Pecoraro M, Panebianco V, Princenthal R, Giganti F. PMID: 42800842 [PubMed - as supplied by publisher]
	A plasma derived hypoxia signature predicts benefit from hypoxia-modifying radiotherapy and reveals dynamic humoral immune modulation in bladder cancer. Br J Cancer Guerrero Quiles C, Abumanhal-Masarweh H, G Abalos J, Lodhi T, Sanchez-Martinez D, Reeves K, James ND, Hall E, Huddart RA, Porta N, Hoskin P, Biolatti LV, Hadjidemetriou M, West CM, Choudhury A. PMID: 42800813 [PubMed - as supplied by publisher]
	Reply to Roberto M. Scarpa's Letter to the Editor re: Paolo Gontero, Richard Perry, Daisy Bridge, et al. Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus. Eur Urol Oncol 2026;9(3):652-9. Eur Urol Oncol Gontero P, Babjuk M. PMID: 42800742 [PubMed - as supplied by publisher]
	Primary ALK-positive anaplastic large cell lymphoma of the urinary bladder in a pediatric patient: a case report and review of literature. J Hematop Kaur N, Aravind A, Jain SP. PMID: 42799861 [PubMed - indexed for MEDLINE]
	Identification and experimental validation of prognostic genes associated with dietary restriction-related signatures in bladder cancer. Front Immunol Wu X, Sun T, Liu Z. PMID: 42798489 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 191603

Page 1 of 9581



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy